Benefits of eprenetapopt plus azacitidine for TP53-mutant MDS and oligoblastic AML Presented ByDr David Sallman, H. Lee Moffitt Cancer Center, FL, USA TrialPhase 2 ConferenceASH 2021 4 February, 2022 11:44
ASH 2021 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceASH 2021 4 January, 2022 08:00